Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $8.6100 (-0.81%) ($8.3300 - $8.7010) on Thu. Oct. 1, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.59% (three month average) | RSI | 67 | Latest Price | $8.6100(-0.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.2% a day on average for past five trading days. | Weekly Trend | HTBX advances 0.3% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(34%) XBI(34%) ARKK(33%) BLOK(31%) IBB(31%) | Factors Impacting HTBX price | HTBX will decline at least -5.795% in a week (0% probabilities). VXX(-20%) VIXM(-19%) UUP(-14%) IGOV(-4%) XLU(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -5.795% (StdDev 11.59%) | Hourly BBV | 0.2 () | Intraday Trend | 0.8% | | | |
|
Resistance Level | $8.65 | 5 Day Moving Average | $8.72(-1.26%) | 10 Day Moving Average | $9.03(-4.65%) | 20 Day Moving Average | $8.65(-0.46%) | To recent high | -66% | To recent low | 45.6% | Market Cap | $947m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |